Archives of Pharmacal Research

, Volume 39, Issue 10, pp 1482–1489 | Cite as

Synergic effect of combination of glycyrol and fluconazole against experimental cutaneous candidiasis due to Candida albicans

  • Zheong-Imm Rhew
  • Yongmoon HanEmail author
Research Article


In this study, we investigated the anti-fungal activity of glycyrol, a coumarine isolated from licorice (Glycyrrhizae Radix), in a murine model of cutaneous candidiasis caused by Candida albicans. Compared to the infected sites, located on the mice’s back, of the untreated control mice, the infected sites treated with glycyrol had reduced CFU (colony forming unit) values up to 60 and 85.5 % at 20 and 40 μg/mouse of glycyrol, respectively (P < 0.01). The antifungal activity of glycyrol was synergistically increased when glycyrol (10 μg/mouse) was combined with fluconazole (10 μg/mouse), demonstrating that the combination therapy is approximately 4 times more effective than fluconazole alone at 20 μg/mouse (P < 0.01). Additionally, the combination activity was 1.65 times greater than the antifungal activity of fluconazole alone at 40 μg/mouse (P < 0.05). In seeking glycyrol’s antifungal mechanism, we determined that glycyrol inhibited hyphal induction and cell wall adherence of C. albicans. Thus, it is very likely that, by damaging the cell wall, glycyrol helps fluconazole invade C. albicans more readily and attack fluconazole’s target in the fungus membrane. In summary, our data indicate that glycyrol may contribute to the development of a novel agent that possesses antifungal activity against cutaneous candidiasis.


Glycyrol Antifungal Cutaneous candidiasis Fluconazole Synergic Combination Mechanism 



We would like to thank Dr. Jue-Hee Lee and Ms. Jue-Young Lee for providing experimental techniques. We would also like to thank Dr. Bruce Granger who helped revise and better the manuscript.

Compliance with ethical standards

Conflict of interest

We, the authors, do not have any conflict of interest.

Supplementary material

12272_2016_824_MOESM1_ESM.doc (27 kb)
Supplementary material 1 (DOC 27 kb)


  1. Berman J, Sudbery PE (2002) Candida albicans: a molecular revolution built on lessons from budding yeast. Nat Rev Genetics 3:918–930CrossRefPubMedGoogle Scholar
  2. Bodey GP (1988) The emergence of fungi as major hospital pathogens. J Hosp Infect 11:411–426CrossRefPubMedGoogle Scholar
  3. Chiew YY, Shepherd MG, Sullivan PA (1980) Regulation of chitin synthesis during germ-tube formation in Candida albicans. Arch Microbiol 125:97–104CrossRefPubMedGoogle Scholar
  4. Cutler JE (1991) Putative virulence factors of Candida albicans. Annu Rev Microbiol 45:187–218CrossRefPubMedGoogle Scholar
  5. Domer JE (1989) Candida cell wall mannan: a polysaccharide with diverse immunologic properties. Crit Rev Microbiol 17:33–51CrossRefPubMedGoogle Scholar
  6. Dubois M, Gilles K, Hamilton JK, Rebers PA, Smith F (1951) A colorimetric method for the determination of sugars. Nature 168:167CrossRefPubMedGoogle Scholar
  7. Edwards JE (1991) Invasive Candida infections: evolution of a fungal pathogen. Engl J Med 324:1060–1062CrossRefGoogle Scholar
  8. Ernst JF, Pla J (2011) Signaling the glycoshield: maintenance of the Candida albicans cell wall. Int J Med Microbiol 301:378–383CrossRefPubMedGoogle Scholar
  9. Fu B, Li H, Wang X, Lee FS, Cui S (2005) Isolation and identification of flavonoids in licorice and a study of their inhibitory effects on tyrosinase. J Agric Food Chem 53:7408–7414CrossRefPubMedGoogle Scholar
  10. Gil C, Pomes R, Nombela C (1990) Isolation and characterization of Candida albicans morphological mutants depressed for the formation of filamentous hypha-type structures. J Bacteriol 172:2384–2391PubMedPubMedCentralGoogle Scholar
  11. Han Y (2007) Synergic anticandidal effect of epigallocatechin-O-gallate combined with amphotericin B in a murine model of disseminated candidiasis and its anticandidal mechanism. Bio Phar Bull 30:1693–1696CrossRefGoogle Scholar
  12. Han Y, Cutler JE (1995) Antibody response that protects against disseminated candidasis. Infect Immun 63:2714–2719PubMedPubMedCentralGoogle Scholar
  13. Han Y, Lee JH (2005) Berberine synergy with amphotericin B against disseminated candidiasis in mice. Bio Pharm Bull 28:541–544CrossRefGoogle Scholar
  14. Han Y, Morrison RP, Cutler JE (1998) A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 66:5771–5776PubMedPubMedCentralGoogle Scholar
  15. Han Y, Ulrich MA, Cutler JE (1999) Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis 179:1477–1484CrossRefPubMedGoogle Scholar
  16. Hatano T, Yasuhara T, Myamoto K, Okuda T (1988) Anti-human immunodeficiency virus phenolics from licorice. Chem Pharm Bull 36:2286–2288CrossRefPubMedGoogle Scholar
  17. Hatano T, Yasuhara T, Fukuda T, Noro T, Okuda T (1989) Phenolic constituents of licorice. II. Structures of licopyranocoumarin, licoarylcoumarin and glisoflavone, and inhibitory effects of licorice phenolics on xanthine oxidase. Chem Pharm Bull 37:3005–3009CrossRefPubMedGoogle Scholar
  18. Khan MS, Malik A, Ahmad I (2012) Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of Candida albicans. Med Mycol 50:33–42CrossRefPubMedGoogle Scholar
  19. Klotz SA, Gaur NK, Rauceo J, Lake DF, Park Y, Hahm KS, Lipke PS (2004) Inhibition of adherence and killing of Candida albicans with a 23-Mer peptide (Fn/23) with dual antifungal properties. Antimicrob Agents Chemother 48:4337–4341CrossRefPubMedPubMedCentralGoogle Scholar
  20. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink CR (1997) Nonfilamentous C. albicans mutants are avirulent. Cell 90:939–949CrossRefPubMedGoogle Scholar
  21. Lynch DP (1994) Oral candidiasis. History, classification and clinical presentation. Oral Surg Oral Med Oral Pathol 78:189–193CrossRefPubMedGoogle Scholar
  22. Maebashi K, Itoyama T, Uchida K, Suegara N, Yamaguchi H (1994) A novel model of cutaneous candidiasis produced in prednisolone-treated guinea-pigs. J Med Vet Mycol 32:349–359CrossRefPubMedGoogle Scholar
  23. Masia Canuto M, Gutierrez Rodero F (2002) Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2:550–563CrossRefPubMedGoogle Scholar
  24. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163CrossRefPubMedPubMedCentralGoogle Scholar
  25. Saitoh T, Shibata S (1969) Chemical studies on the oriental plant drugs. XXII. Some new constituents of licorice root. (2). Glycyrol, 5-O-methylglycyrol and isoglycyrol. Chem Pharm Bull 17:729–734CrossRefPubMedGoogle Scholar
  26. Sanglard D (2002) Clinical relevance of mechanism of antifungal drug resistance in yeasts. Enferm Infecc Microbiol Clin 20:462–469CrossRefPubMedGoogle Scholar
  27. Schaberg DR, Culver DH, Gayner RP (1991) Major trends in the microbial etiological nosocomial infection. Am J Med 16:72S–75SCrossRefGoogle Scholar
  28. Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Bradley B, Weinstein J (1995) Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 172:1263–1268CrossRefPubMedGoogle Scholar
  29. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR (1998) Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 178:203–211CrossRefPubMedGoogle Scholar
  30. Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy PR, Heine D, Willems MW, Panzer H, Wittes H (2001) Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 185:363–369CrossRefPubMedGoogle Scholar
  31. Tanaka Y, Kikuzaki H, Fukuda S, Nakatani N (2001) Antibacterial compounds of licorice against upper airway respiratory tract pathogens. J Nutr Sci Vitaminol 47:270–273CrossRefPubMedGoogle Scholar
  32. Tsukamoto S, Aburatani M, Yoshida T, Yamashita Y, El-Beih AA, Ohta T (2005) CYP3A4 inhibitors isolated from licorice. Bio Pharm Bull 28:2000–2002CrossRefGoogle Scholar
  33. Villar CC, Kashleva H, Mitchel AP, Dongari-Bagtzoglou A (2005) Invasive phenotype of Candida albicans affects the host proinflammatory response to infection. Infect Immun 73:4588–4595CrossRefPubMedPubMedCentralGoogle Scholar
  34. White TC (1997) The presence of an R467 K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α demethylase in Candida albicans. Antimicrob Agents Chemother 41:1488–1494PubMedPubMedCentralGoogle Scholar
  35. Whiteway M, Oberholzer U (2004) Candida morphogenesis and hostpathogen interactions. Curr Opin Microbiol 7:350–357CrossRefPubMedGoogle Scholar
  36. Zakula D, Capobianco JO, Goldman RC (1997) Novel antifungal agents which inhibit lanosterol 14α-demethylase in Candida albicans CCH442. J Antimicrob Chemother 39:261–264CrossRefPubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2016

Authors and Affiliations

  1. 1.Department of ImmunoMicrobiology, College of PharmacyDongduk Women’s UniversitySeoulKorea

Personalised recommendations